Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation
Year: 2013
Type: article
Study design: Observational Study
Abstract: Initiation of antiretroviral therapy during acute HIV-1 infection may prevent persistent immune activation. We analyzed longitudinal CD38+HLA-DR+ CD8+ T-cell percentages in 31 acutely infected individuals who started early (median 43 days since infection) and successful antiretroviral therapy, and maintained viral suppression through 96 weeks. Pretherapy a median of 72.6% CD8+ T cells were CD38+HLA-DR+, and although this decreased to 15.6% by 96 weeks, it remained substantially higher than seronegative controls (median 8.9%, P = 0.008). Shorter time to suppression predicted lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1 pathogenesis may result in prolonged immune dysfunction.
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Funders: Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, ViiV Healthcare, National Institutes of Health, Center for AIDS Research, University of Washington, National Institute of Allergy and Infectious Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences, Center for AIDS Research, University of North Carolina at Chapel Hill
Awards: Infectious Diseases in Africa: Immune Escape and HIV Vaccines, G2215493674, Poly-functional analyses of vaccine-induced T cell responses, UNC Clinical and Translational Science Award, G668731788, Midcareer Investigator Award /Patient-Oriented Research, G8247407632, G8776006352, Training in Sexually Transmitted Infections and HIV, The University of North Carolina Center for AIDS Research, Center for AIDS Research
OpenAlex ID: W2020635157